About Murli Krishna Pharma Private Limited
Data last updated:
Murli Krishna Pharma Private Limited is a private limited company based in Pune, Maharashtra, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 02 April 2004 and has been in existence for over 22 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN U24230PN2004PTC206917. Its GSTIN is 27AADCM8601K1ZB (Maharashtra).
The company has an authorised share capital of ₹32.5 Cr and a paid-up capital of ₹5.39 Cr. It is led by directors including Satya Ramani Vadlamani (Managing Director) and Venkat Murli Krishna Vadlamani.
Its last annual general meeting (AGM) was held on 31 December 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at D – 98 Ranjangaon MIDC Tal Shirur, Pune, Maharashtra, India – 412209.
As per the financials filed for FY 2025, the company reported a revenue of ₹146.68 Cr, a decline of 21% compared to the previous year. For the same year it recorded a net profit of ₹1.74 Cr (net margin 1.2%) and EBITDA of ₹10.33 Cr (EBITDA margin 7%). Revenue has grown at a compounded annual rate (CAGR) of 11% over three years and 15% over five years.
The company has about 218 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Murli Krishna Pharma. As per MCA filings, the company has open charges of ₹81.98 Cr and satisfied charges of ₹13.76 Cr on record. Court records list 13 cases involving the company, including 5 filed by the company and 8 filed against it; 3 cases are pending. The company has 25 deals on record (13 secondary share transfers, 12 funding rounds), with disclosed funding of ₹90.38 Cr; the latest was in December 2023. Its 10 peer companies in the Pharma industry (Formulations) are compared by revenue, 5 larger and 5 smaller; the largest is Zydus Pharmaceuticals Limited with revenue of ₹148.75 Cr. The company has 5 MSME Form 1 returns on record between 2019 and 2023, listing 840 overdue payments to 26 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website murlikrishnapharma.com.
- EmailLocked
- TelephoneLocked
- Website
- Social Media
- Registered AddressD – 98 Ranjangaon MIDC Tal Shirur, Pune, Maharashtra, India – 412209
- IndustryPharma, Drug Formulation & Development
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Murli Krishna Pharma Private Limited
The main business activity of Murli Krishna Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Murli Krishna Pharma Private Limited FY 2025 filings available
Murli Krishna Pharma Private Limited reported revenue of ₹146.68 Cr (down 21% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Murli Krishna Pharma Private Limited
Revenue fell 21% in the latest year, but over five years it has grown at a compounded annual rate (CAGR) of 15%. EBITDA fell 37% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Murli Krishna Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | ₹146.68 Cr | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹10.33 Cr | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹1.74 Cr | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Murli Krishna Pharma Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 7% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 1.2% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Murli Krishna Pharma are in the company report.
Financial statements from 2015
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Peer Comparison of Murli Krishna Pharma Private Limited
Murli Krishna Pharma Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Formulations). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Zydus Pharmaceuticals Limited | ₹148.75 Cr (FY 2025) | •••• | •••• | 110.0% | •••• | Ahmedabad, Gujarat, India |
| Bafna Pharmaceuticals Limited Listed | ₹148.6 Cr (FY 2025) | •••• | •••• | -5.0% | •••• | Chennai, Tamil Nadu, India |
| Celon Laboratories Private Limited | ₹148.17 Cr (FY 2025) | •••• | •••• | -7.0% | •••• | Hyderabad, Telangana, India |
| Unosource Pharma Limited | ₹147.51 Cr (FY 2025) | •••• | •••• | 14.0% | •••• | Delhi, India |
| Canton Laboratories Private Limited | ₹147.08 Cr (FY 2025) | •••• | •••• | 26.0% | •••• | Vadodara, Gujarat, India |
| Murli Krishna Pharma Private Limited this company | ₹146.68 Cr (FY 2025) | •••• | •••• | -21.0% | •••• | Pune, Maharashtra, India |
| Raman & Weil Private Limited | ₹145.87 Cr (FY 2025) | •••• | •••• | 7.0% | •••• | Mumbai, Maharashtra, India |
| Pulse Pharmaceuticals Private Limited | ₹145.08 Cr (FY 2024) | •••• | •••• | -1.0% | •••• | Hyderabad, Telangana, India |
| HBC Lifesciences Private Limited | ₹144.64 Cr (FY 2024) | •••• | •••• | 17.0% | •••• | Gandhinagar, Gujarat, India |
| Goodway Chemicals Private Limited | ₹144.1 Cr (FY 2025) | •••• | •••• | -12.0% | •••• | Mumbai, Maharashtra, India |
| Afrinext Overseas Private Limited | ₹144.02 Cr (FY 2025) | •••• | •••• | 65.0% | •••• | Vadodara, Gujarat, India |
Peers are the five companies nearest above and the five nearest below Murli Krishna Pharma by revenue in the Pharma industry (Formulations), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Auditor Details of Murli Krishna Pharma Private Limited
Murli Krishna Pharma Private Limited is audited by M S K A & Associates for the financial year 2025.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| M S K A & Associates | Locked | Locked | Locked |
Complete auditor history
Appointment and cessation dates and past auditor changes are in the company report.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Murli Krishna Pharma Private Limited
Murli Krishna Pharma has 4 current directors and 10 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Nithyagovind Also directs: Indilyfe Sponsor LLP, Fleming Laboratories Limited, Biome Biologicals Private Limited and 4 more | Nominee Director | 27 May 2020 | 6 Years 4 Months | Current |
| Satya Ramani Vadlamani | Managing Director | 02 Apr 2004 | 22 Years 6 Months | Current |
| Venkat Murli Krishna Vadlamani | Director | 15 Jul 2024 | 2 Years 2 Months | Current |
| Vijay Shastri Kalyanasundaram | Director | 02 Apr 2004 | 22 Years 6 Months | Current |
Ownership and Shareholding of Murli Krishna Pharma Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Murli Krishna Pharma Private Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 22 Aug 2025 | Hdfc Bank Limited | ₹30 Lakh | Open |
| 28 Jun 2024 | Others | ₹10 Cr | Open |
| 28 Jun 2024 | Others | ₹10 Cr | Open |
| 04 Sep 2023 | Axis Bank Limited | ₹1.3 Cr | Open |
| 09 May 2023 | Hdfc Bank Limited | ₹23.02 Lakh | Open |
Total charge records: 12 View all charges
Deals & Funding of Murli Krishna Pharma Private Limited
Murli Krishna Pharma Private Limited has 25 deals on record (13 secondary share transfers, 12 funding rounds), with disclosed funding of ₹90.38 Cr; the latest was in December 2023.
Deals on record (5 of 25)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Dec 2023 | Secondary share transfer | Undisclosed | Buyer: 2 individuals Seller: Murli Krishna Exports Private Limited , an individual |
| Sep 2023 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Apr 2023 | Secondary share transfer | Undisclosed | Buyer: an individual Seller: an individual |
| Mar 2010 | Funding round | ₹75.8 Lakh | Investors: Krutow International Inc, 3 individuals |
| Dec 2007 | Funding round | ₹44 Lakh | Investors: Murli Krishna Exports Private Limited , 3 individuals |
Full deal history
All 25 deals with amounts, valuations, instruments and every party are in the company report.
- Every funding round and share transfer
- Amounts and valuations
- Investors, buyers and sellers
- Instruments and deal dates
Verified entity values are shown only after access is granted.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal Cases of Murli Krishna Pharma Private Limited
Murli Krishna Pharma Private Limited has 13 court cases on record: 5 filed by Murli Krishna Pharma, 8 filed against it. 3 cases are pending and 10 are disposed. Status as checked between 21 Sep 2026 and 04 Oct 2026.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 10 | 8 | 2 |
| High courts | 3 | 0 | 1 |
Cases on record (5 of 13)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by Symbio Generrics India Private Limited | Pending |
| District court, Hyderabad CCC, Telangana | Cheque dishonour complaint | Filed against the company by Vasudha Pharma Chem Limited | Disposed |
| District court, BENGALURU, Karnataka | Criminal complaint | Filed against the company by Symbio Generrics India Private Limited | Disposed |
| District court, Mumbai City Civil Court, Maharashtra | Interim or miscellaneous application | Filed by the company against Hapag-Lloyd India Private Limited | Disposed |
| District court, Maharashtra Industrial and Lab, Maharashtra | Interim or miscellaneous application | Filed against the company by Murli Krishna Pharma Kamgar Sanghtana | Pending |
Full case history
All 13 cases with case numbers, court, year-wise trend, opposite parties and decision dates are in the company report.
- Every case with its case number
- Year-wise trend
- Opposite parties
- Decision dates and orders
Verified entity values are shown only after access is granted.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME Payment Delays by Murli Krishna Pharma Private Limited
Murli Krishna Pharma Private Limited has 5 MSME Form 1 returns on record between 2019 and 2023, listing 840 overdue payments to 26 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 26)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| Anish Pharmaequip Private Limited | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
| an individual supplier | •••• | •••• | •••• |
Full MSME payment history
Every supplier, amount and due date from all 5 MSME Form 1 returns is in the company report.
- Every reported supplier due
- Amounts and due dates
- Reasons given in each return
- Period-by-period history
Verified entity values are shown only after access is granted.
Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.
Associated Brands with Murli Krishna Pharma Private Limited
Murli Krishna Pharma operates one associated brand: Murli Krishna Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Formulation intermediate drugs are manufactured by the company. | murlikrishnapharma.com |
Employees and EPFO Compliance at Murli Krishna Pharma Private Limited
Murli Krishna Pharma Private Limited has a workforce of 218 employees as of Sep 26, 2025.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
CIN History of Murli Krishna Pharma Private Limited
Murli Krishna Pharma has one previous CIN (Corporate Identification Number): U24230MH2004PTC145510. The current CIN is U24230PN2004PTC206917, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| U24230PN2004PTC206917 | Current |
| U24230MH2004PTC145510 | Previous |
News related to Murli Krishna Pharma Private Limited
Recent Activity on Murli Krishna Pharma Private Limited
Murli Krishna Pharma Private Limited has 15 board changes on record since 2004: 5 appointments and 10 cessations. The latest: Venkat Murli Krishna Vadlamani ceased to be Additional Director on 02 Dec 2024.
26 earlier events are listed in the company report.
Credit Ratings, Litigation & Regulatory Alerts for Murli Krishna Pharma Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Murli Krishna Pharma Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Murli Krishna Pharma Private Limited
Murli Krishna Pharma has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AADCM8601K1ZB | Maharashtra | Active | 01 Jul 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Murli Krishna Pharma Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Murli Krishna Pharma Private Limited
Murli Krishna Pharma is an active private limited company based in Pune, Maharashtra, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 02 April 2004 (22+ years old) and is registered under CIN U24230PN2004PTC206917.
Murli Krishna Pharma reported revenue of ₹146.68 Cr for FY 2025 (down 21% YoY).
Murli Krishna Pharma has 4 current directors:
- Satya Ramani Vadlamani - Managing Director
- Nithyagovind - Nominee Director
- Venkat Murli Krishna Vadlamani - Director
- Vijay Shastri Kalyanasundaram - Director
Murli Krishna Pharma reported a net profit of ₹1.74 Cr (net margin 1.2%) and EBITDA of ₹10.33 Cr (EBITDA margin 7%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Murli Krishna Pharma is 11% over three years and 15% over five years. In the latest year (FY 2025) revenue fell 21%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Murli Krishna Pharma is 27AADCM8601K1ZB, registered in Maharashtra.
The CIN (Corporate Identification Number) of Murli Krishna Pharma is U24230PN2004PTC206917. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Murli Krishna Pharma has 13 court cases on record: 5 filed by the company and 8 filed against it. 3 are pending. Most are in the district courts.
Murli Krishna Pharma was incorporated on 02 April 2004, making it 22+ years old. It is registered with the Registrar of Companies, Pune.
Murli Krishna Pharma has 25 deals on record (13 secondary share transfers, 12 funding rounds), with disclosed funding of ₹90.38 Cr; the latest was in December 2023.
The peers of Murli Krishna Pharma by revenue are Zydus Pharmaceuticals Limited, Bafna Pharmaceuticals Limited, Celon Laboratories Private Limited, Unosource Pharma Limited, Canton Laboratories Private Limited and 5 more, all in the Pharma industry (Formulations).
Venkat Murli Krishna Vadlamani ceased to be Additional Director on 02 Dec 2024. Venkat Murli Krishna Vadlamani was appointed as Director on 15 Jul 2024. Zainul Fakhruddin Bharmal ceased to be Director on 08 Aug 2022. Murli Krishna Pharma has 15 board changes on record in total.